Boston Partners Astrazeneca PLC Transaction History

Boston Partners

$90.9 Billion
Q3 2025

A detailed history of Boston Partners transactions in Astrazeneca PLC stock. As of the latest transaction made, Boston Partners holds 5,247,449 shares of AZN stock, worth $469 Million. This represents 0.44% of its overall portfolio holdings.

Number of Shares

5,247,449

Previous 4,989,924 5.16%

Holding current value

$469 Million

Previous $349 Million 15.45%

% of portfolio

0.44%

Previous 0.41%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	BUY	$68.72 - $82.11 $17.7 Million - $21.1 Million	257,525 Added 5.16%	5,247,449 $403 Million
Q2 2025 Aug 12, 2025	BUY	$64.87 - $75.0 $693,914 - $802,275	10,697 Added 0.21%	4,989,924 $349 Million
Q2 2025 Aug 07, 2025	SELL	$64.87 - $75.0 $3.72 Million - $4.31 Million	-57,418 Reduced 1.14%	4,979,227 $348 Million
Q1 2025 May 12, 2025	BUY	$65.37 - $77.96 $86.9 Million - $104 Million	1,329,166 Added 35.85%	5,036,645 $370 Million
Q4 2024 Feb 10, 2025	BUY	$63.2 - $79.58 $232 Million - $292 Million	3,670,719 Added 9985.63%	3,707,479 $243 Million

Q3 2024 Nov 12, 2024	BUY	$76.67 - $87.62 $2.52 Million - $2.88 Million	32,814 Added 831.58%	36,760 $2.86 Million
Q2 2024 Aug 13, 2024	SELL	$66.81 - $80.83 $36,344 - $43,971	-544 Reduced 12.12%	3,946 $307,000
Q1 2024 May 13, 2024	BUY	$61.03 - $69.57 $274,024 - $312,369	4,490 New	4,490 $304,000
Q3 2023 Nov 07, 2023	BUY	$64.85 - $71.7 $3,696 - $4,086	57 Added 1.87%	3,107 $210,000
Q2 2023 Aug 10, 2023	SELL	$69.91 - $75.81 $40,897 - $44,348	-585 Reduced 16.09%	3,050 $218,000
Q1 2023 May 09, 2023	BUY	$63.15 - $71.6 $229,550 - $260,265	3,635 New	3,635 $252,000

Others Institutions Holding AZN

# of Institutions

1,497

Shares Held

500M

Call Options Held

5.59M

Put Options Held

3.18M

View Full List

About ASTRAZENECA PLC

Ticker AZN
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 3,099,020,032
Market Cap $277B
Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...

More about AZN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Boston Partners, based on Form 13F filings with the SEC.

News

Stay updated on Boston Partners with notifications on news.

Account